XML 32 R21.htm IDEA: XBRL DOCUMENT

Subsequent Event (Notes)	3 Months Ended
Subsequent Event (Notes)	Mar. 31, 2019
Subsequent Event [Abstract]
Subsequent Events [Text Block]	Subsequent Event Pursuant to its collaboration with Celgene, the Company has been developing an in vitro diagnostic test, LymphMark, as a potential companion diagnostic to aid in identifying patients with diffuse large B-cell lymphoma (DLBCL) for treatment. In April 2019, Celgene announced that the trial evaluating REVLIMID® for the treatment of DLBCL did not meet its primary endpoint and, therefore, the Company does not expect to file a pre-market approval for LymphMark as a companion diagnostic for REVLIMID. As a result of this outcome, the Company expects that its collaboration agreement with Celgene will be terminated.